SREBF1 and Insulin resistance: Impairment of lipid metabolism and insulin resistance leads to the inhibition of glycogen synthesis enzymes and redirects glucose to the lipogenic pathway, stimulating SREBP1c and its downstream targets and increasing intrahepatic TAG production [11].